BidaskClub downgraded shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a hold rating to a sell rating in a report released on Saturday morning.
Several other research firms have also recently issued reports on AMAG. ValuEngine upgraded shares of AMAG Pharmaceuticals from a buy rating to a strong-buy rating in a report on Wednesday, June 6th. Leerink Swann began coverage on shares of AMAG Pharmaceuticals in a report on Monday, May 21st. They issued a market perform rating and a $24.65 price objective for the company. B. Riley upgraded shares of AMAG Pharmaceuticals from a neutral rating to a buy rating and increased their price objective for the company from $23.00 to $30.00 in a report on Friday, June 15th. Janney Montgomery Scott cut shares of AMAG Pharmaceuticals from a buy rating to a neutral rating and set a $20.00 price objective for the company. in a report on Friday, June 15th. Finally, Cantor Fitzgerald reiterated a hold rating and issued a $18.00 price objective (up from $17.00) on shares of AMAG Pharmaceuticals in a report on Friday, August 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $22.85.
AMAG Pharmaceuticals stock opened at $22.45 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.95 and a current ratio of 2.06. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $26.10.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.54). The company had revenue of $146.25 million during the quarter, compared to the consensus estimate of $156.26 million. AMAG Pharmaceuticals had a negative net margin of 36.87% and a negative return on equity of 2.77%. The company’s revenue was up 12.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.40) earnings per share. research analysts predict that AMAG Pharmaceuticals will post -3.43 EPS for the current year.
In related news, CEO William K. Heiden sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the chief executive officer now directly owns 328,015 shares of the company’s stock, valued at $8,200,375. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.00% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its stake in AMAG Pharmaceuticals by 6.0% during the second quarter. Legal & General Group Plc now owns 67,795 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after purchasing an additional 3,827 shares during the last quarter. Alps Advisors Inc. lifted its stake in AMAG Pharmaceuticals by 9.0% during the second quarter. Alps Advisors Inc. now owns 49,816 shares of the specialty pharmaceutical company’s stock valued at $971,000 after purchasing an additional 4,096 shares during the last quarter. Northern Trust Corp lifted its stake in AMAG Pharmaceuticals by 1.0% during the first quarter. Northern Trust Corp now owns 458,445 shares of the specialty pharmaceutical company’s stock valued at $9,237,000 after purchasing an additional 4,468 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in AMAG Pharmaceuticals by 8.5% during the second quarter. BNP Paribas Arbitrage SA now owns 88,180 shares of the specialty pharmaceutical company’s stock valued at $1,720,000 after purchasing an additional 6,883 shares during the last quarter. Finally, Swiss National Bank lifted its stake in AMAG Pharmaceuticals by 13.0% during the first quarter. Swiss National Bank now owns 63,457 shares of the specialty pharmaceutical company’s stock valued at $1,279,000 after purchasing an additional 7,300 shares during the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Article: Stock Symbols and CUSIP Explained
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.